智通财经APP获悉，心脏植入物开发商Encore Medical周二公布了其首次公开募股(IPO)条款。该公司计划以每股5美元的价格发行300万股股票，筹资1500万美元。该公司计划在纽交所上市，股票代码为“EMI”。
据悉，Encore Medical总部位于美国明尼苏达州伊根。该公司开发和生产室间隔闭塞装置，这是一种通过导管输送的植入式产品，用于修复某些心脏缺陷，如卵圆孔未闭(PFO)。该公司的设备已被批准在欧盟销售，虽然它还没有获得在美国销售其设备的监管批准，但该公司已获得美国食品药品管理局(FDA)的批准，可以进行试验以获得市场许可。数据显示，该公司在截至2025年9月30日的12个月营收为200万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.